^
    8d
    Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer. (PubMed, Pharmacol Res)
    The FDA has approved four PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) for the treatment of ovarian, breast, prostate, and pancreatic cancer...The Chinese NMPA has approved three PARP antagonists (fuzuloparib, pamiparib, senaparib) for the treatment of ovarian cancer. All seven of these drugs are orally bioavailable and fall within the criteria of Lipinski's rule of five. Drug resistance develops in most PARP-inhibitor-treated cancer patients within one or two years.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib) • Partruvix (pamiparib) • AiRuiYi (fluzoparib) • Paishuning (senaparib)
    8d
    Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy. (PubMed, Expert Rev Anticancer Ther)
    Notably, senaparib showed superior PFS efficacy compared to veliparib and niraparib. PARPi showed efficacy in improving PFS as maintenance therapy for newly diagnosed advanced OC, although no OS advantage was observed. PROSPERO (CRD420251020275).
    Retrospective data • Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA wild-type • BRCA mutation
    |
    Zejula (niraparib) • veliparib (ABT-888) • Paishuning (senaparib)
    1m
    PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis. (PubMed, JAMA Netw Open)
    Observed treatment efficacy and toxic effects varied across PARP inhibitor regimens; for example, the risk ratio for any recurrence or death in the overall study group ranged from 0.53 (95% CI, 0.40-0.70) for senaparib to 0.83 (95% CI, 0.68-1.00) for olaparib, while the risk ratio for high-grade adverse events ranged from 1.15 (95% CI, 0.64-2.06) for veliparib to 4.73 (95% CI, 2.77-8.07) for niraparib. In this study, no subgroup showed an association between first-line PARP inhibitor maintenance therapy in advanced-stage EOC and improved OS, and findings suggest that the consistency of associated PFS benefits may vary, particularly in homologous recombination proficient and BRCA wild type tumors. Variability in efficacy and toxic effects across subgroups and PARP inhibitor regimens underscores the importance of individualized treatment decisions.
    Clinical • Retrospective data • Review • Journal
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA wild-type
    |
    Lynparza (olaparib) • Zejula (niraparib) • veliparib (ABT-888) • Paishuning (senaparib)
    1m
    Senaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer with Homologous Recombination Proficient and Exploration of Biomarkers (ChiCTR2500109579)
    P4, N=37, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P4 trial
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • Paishuning (senaparib)
    1m
    Efficacy and safety of maintenance therapy with senaparib in patients with platinum-sensitive recurrent ovarian cancer previously treated with PARP inhibitors (ChiCTR2500108180)
    P4, N=40, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P4 trial • Platinum sensitive
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA wild-type • BRCA mutation
    |
    Paishuning (senaparib)
    3ms
    A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects (clinicaltrials.gov)
    P1, N=6, Completed, Impact Therapeutics, Inc. | Not yet recruiting --> Completed
    Trial completion
    |
    Paishuning (senaparib)
    3ms
    An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition (clinicaltrials.gov)
    P1, N=28, Completed, Impact Therapeutics, Inc. | Not yet recruiting --> Completed
    Trial completion
    |
    Paishuning (senaparib)
    3ms
    SABRINA: Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer (clinicaltrials.gov)
    P2, N=93, Completed, Impact Therapeutics, Inc. | Recruiting --> Completed | Trial completion date: Aug 2022 --> Dec 2024
    Trial completion • Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    Paishuning (senaparib)
    3ms
    An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition (clinicaltrials.gov)
    P1, N=36, Completed, Impact Therapeutics, Inc. | Not yet recruiting --> Completed
    Trial completion
    |
    Paishuning (senaparib)
    4ms
    Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker (clinicaltrials.gov)
    P2, N=37, Not yet recruiting, Fudan University
    New P2 trial
    |
    Avastin (bevacizumab) • Paishuning (senaparib)
    5ms
    Senaparib: First Approval. (PubMed, Drugs)
    Senaparib (®; Sainapali Jiaonang) is a novel PARP inhibitor that potently inhibits PARP1 and PARP2, which is being developed by IMPACT Therapeutics for the treatment of advanced ovarian cancer and small-cell lung cancer. This article summarizes the milestones in the development of senaparib leading to this first approval for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who achieved a complete or partial response to first-line platinum-based chemotherapy.
    Journal
    |
    PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    Paishuning (senaparib)
    5ms
    A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients with Advanced Solid Tumors (ACTRN12616000689471)
    P1, N=30, Completed, IMPACT Therapeutics Australia Pty Ltd | Recruiting --> Completed
    Trial completion
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Paishuning (senaparib)